Overview of Adalat LA

Property	Description
Active Ingredient	Nifedipine
Form	Prolonged-release tablet
Pharmacological Class	Selective Calcium Channel Blocker (Dihydropyridine)
General Purpose	Reducing systemic blood pressure and arterial resistance
Origin	Synthetic derivative

Adalat LA is the trade name for a specialized synthetic medication containing the active ingredient Nifedipine. This drug is precisely classified as a highly selective calcium channel blocker (CCB), belonging to the scientific group known as dihydropyridine derivatives. It is provided as a single-ingredient product intended for oral administration, typically requiring a prescription-only (Rx) status.

The Core Identity and Classification of Adalat LA

Adalat LA is a medication whose primary function is to influence the movement of calcium ions within the walls of blood vessels. As a selective calcium channel blocker, its main target is the vascular smooth muscle, minimizing the effects on the heart’s conduction system compared to non-selective calcium antagonists. The Nifedipine compound acts specifically by blocking voltage-dependent L-type calcium channels. This mechanism is clinically recognized for its role in modifying vascular resistance across pharmacological studies.

Understanding the Prolonged-Release Tablet (LA) Formulation

The LA in Adalat LA stands for Long Acting, identifying it as a prolonged-release tablet (or extended-release preparation). This oral form is engineered with a complex polymer matrix that controls the rate at which Nifedipine is released into the body. This controlled delivery mechanism is the drug's distinctive feature, designed to ensure a steady, consistent concentration of the active ingredient, eliminating the rapid peaks and troughs associated with immediate-release formulations. This stability is essential for maintaining a stable, sustained 24-hour anti-hypertensive effect throughout the day.

General Purpose: Targeting Peripheral Resistance

The general purpose of this medication is to cause peripheral arterial vasodilatation, meaning it helps the small arteries to relax and widen. By relaxing the vascular smooth muscle, the drug reduces the mechanical resistance to blood flow throughout the body. This reduction in peripheral resistance and the easing of the heart's workload provides a core benefit for lowering high systemic blood pressure (acting as an antihypertensive agent) and relieving discomfort associated with reduced blood supply in the coronary arteries (angina).

Regulatory References

National Institutes of Health (NIH)

What side effects are possible with Adalat LA?

Possible side effects and safety information

The safety profile for Adalat LA (Nifedipine) is officially classified by frequency and System-Organ Class, reflecting data documented in regulatory prescribing information. Understanding these classifications is key to defining the medicine's risk profile.

Adverse Reactions Classified by Frequency

The most frequently documented adverse reaction is headache, which is officially classified as Very Common (occurring in 1 in 10 patients or more). Common effects (occurring in 1 in 100 to 1 in 10 patients) often relate to the drug's vasodilatory activity and include flushing, peripheral oedema (swelling), dizziness, tachycardia, and constipation.

Uncommon and Rare effects are also documented, including gastrointestinal discomfort, nervousness, skin reactions, and changes in blood pressure leading to hypotension.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain adverse reactions that, though uncommon, are considered clinically significant. These include severe immune responses such as anaphylactic reactions and life-threatening skin disorders like Toxic Epidermal Necrolysis. A paradoxical increase in angina attacks may occur, particularly at the initiation of treatment or following a dose increase.

The medication is strictly restricted in specific clinical situations, including Cardiogenic Shock and severe Aortic Stenosis. Its use is also contraindicated with the concurrent administration of Rifampicin, as this combination affects the drug's metabolism and efficacy.

Population and Exposure-Related Safety Notes

The official label requires caution in patients with hepatic impairment, as Nifedipine is extensively metabolized by the liver, potentially leading to increased concentrations. The clearance of the drug is also noted to be reduced in older adults. Furthermore, the development of gingival hyperplasia is a recognized safety pattern associated with long-term exposure to this class of medication.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Adalat LA (Nifedipine) is formally documented in regulatory sources as an acute and potentially severe medical event. The clinical manifestations primarily reflect an excessive exaggeration of the drug's effect, leading to critical changes in the cardiovascular system.

Documented manifestations include severe, sustained hypotension (extremely low blood pressure) and significant disturbances in heart rate, such as reflex tachycardia or bradycardia. Physiological findings may also include metabolic acidosis and elevated blood sugar levels (hyperglycemia). Severe outcomes officially listed in prescribing information include the risk of circulatory collapse, cardiogenic shock, and cardiac arrest.

Emergency Action Requirement

Due to the life-threatening potential of these manifestations, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Because Adalat LA is a prolonged-release formulation, the absorption of the active ingredient can be delayed and sustained over many hours. This unique factor requires extended hospital observation and monitoring, even if initial symptoms appear mild.

Management Protocol

There is no specific antidote known for Nifedipine overdose. Management procedures described in official documents are symptomatic and supportive, and may include gastrointestinal decontamination (e.g., gastric lavage or activated charcoal), as well as the administration of intravenous calcium salts or vasopressors to stabilize critical hemodynamic parameters.

Therapeutic Uses of Adalat LA

What Adalat LA Treats: Main Uses and Benefits

Adalat LA may be part of symptomatic management, providing support across key cardiovascular conditions characterized by episodic or disruptive symptom patterns. It is generally applied in contexts where additional assistance is needed for long-term symptom management and maintaining daily stability.

Managing Persistent High Blood Pressure (Hypertension)

This medication is commonly used to help with pronounced symptoms and manifestations associated with high blood pressure, playing a role in the management of this condition. The two core condition categories it is used for are persistent high blood pressure and chronic stable chest pain (angina). It is considered relevant in situations where the underlying condition may create noticeable interference with general stability. The medication may assist with maintaining functional stability during periods of heightened physiological stress.

“The medication may be relevant in clinical settings that involve acute or unstable symptom patterns, offering support during difficult episodes by easing distress.”

Easing Symptoms of Chronic Stable Angina Pectoris

Adalat LA offers a supportive therapeutic benefit by helping to manage the intensity of symptoms in chronic stable angina. It is applied in conditions marked by episodic or fluctuating symptom patterns of chest discomfort. The medication offers symptomatic relief that helps patients cope more steadily, supporting general well-being during symptomatic phases.

Quick Fact: Support for Episodic Symptoms Adalat LA is considered relevant in situations involving recurrent or episodic manifestations, assisting with managing groups of symptoms that may intensify temporarily.

Regulatory References

Irish Health Products Regulatory Authority

Eligibility and Restrictions for Use

This section explains the officially documented eligibility and non-eligibility rules for Adalat LA (Nifedipine prolonged-release), based strictly on regulatory prescribing information.

Populations Who Cannot Use Adalat LA (Contraindications)

The medicine is contraindicated and must not be used in the following conditions or patient groups:

Hypersensitivity to Nifedipine, other dihydropyridines, or any excipients.
Cardiovascular shock, unstable angina, or a heart attack within the past month.
Clinically significant aortic stenosis.
Severe gastrointestinal stenosis or obstruction, including patients with a Kock pouch (ileostomy after proctocolectomy).
Concomitant treatment with the antibiotic Rifampicin.

Age and Conditional Use

Age Group	Regulatory Status
Children/Adolescents (Under 18)	Not intended for use; safety and efficacy not established.
Older Adults (Over 65)	Generally permitted; no routine dose adjustment needed, but monitoring is advised.

Condition	Conditional Use Statement
Severe Hepatic Impairment	Requires careful monitoring and may necessitate a dose reduction.
Severe Hypotension	Requires particularly careful medical surveillance (systolic BP < 90 mmHg).

Pregnancy and Lactation Eligibility Status

Use is contraindicated before the 20th week of pregnancy.
Use is generally not recommended during breastfeeding.
For severe hypertension after 20 weeks of pregnancy, use may be permitted only when the benefit is judged to outweigh the potential risk.

What should I know about interactions with other medicines?

Adalat LA (nifedipine) interacts with certain other medicines and products, primarily by influencing how the body processes the medication.

Contraindicated and Restricted Combinations

Rifampicin: This antibiotic must not be taken with Adalat LA. Rifampicin is a strong inducer of the CYP3A4 enzyme, which is the main system that breaks down nifedipine. Combining these two drugs will severely reduce the amount of nifedipine in the bloodstream, making it ineffective.
Grapefruit Juice: You must avoid drinking grapefruit juice or eating grapefruit while taking Adalat LA. Grapefruit contains substances that inhibit the same enzyme (CYP3A4), which significantly increases the level of nifedipine in the blood, leading to a higher risk of side effects or excessive blood pressure lowering.

Interactions Requiring Close Monitoring

Many interactions relate to drugs that affect the CYP3A4 enzyme system. Your doctor may need to adjust your dose or monitor you closely if you take Adalat LA with:

CYP3A4 Inhibitors: Medications that slow the breakdown of nifedipine, potentially increasing its effects. This group includes certain macrolide antibiotics (e.g., erythromycin), antifungal medications (e.g., ketoconazole, itraconazole), and certain HIV protease inhibitors (e.g., ritonavir, indinavir).
CYP3A4 Inducers: Medications that speed up the breakdown of nifedipine, potentially decreasing its effectiveness. Examples include certain antiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital).
Other Blood Pressure Agents: Combining Adalat LA with other blood pressure-lowering drugs (including beta-blockers) may cause an additive effect, requiring monitoring for a significant drop in blood pressure.
Specific Medications: Close monitoring of drug levels and dose adjustments are needed if taking Adalat LA with Tacrolimus (an immunosuppressant) or Quinidine (an anti-arrhythmic), as Adalat LA can affect the levels of these drugs in the body.

Mechanism of Action

Adalat LA (Nifedipine) acts as a highly selective inhibitor within the circulatory system, operating through two primary mechanistic domains that lead to changes in vascular tone and resistance.

Molecular Blockade of L-Type Calcium Channels

This mechanism begins with the active ingredient selectively blocking the L-type Voltage-Gated Calcium Channel ( Ca V1.2) found mainly in the membranes of arterial smooth muscle cells. By inhibiting the essential influx of extracellular calcium ions ( Ca^2+), the drug shuts down the molecular trigger required for muscle contraction.

Modulation of Arterial Tone and Systemic Resistance

The resulting lack of intracellular Ca^2+ disrupts the excitation-contraction coupling pathway, preventing the formation of the actin-myosin cross-bridges that cause muscle shortening. This disruption leads to generalized relaxation and widening of the arteries (vasodilation). The physiological consequence of this vasodilation is a reduction in the overall Systemic Vascular Resistance (SVR).

Sustained Mechanism and Compensatory Dynamics

The prolonged-release (LA) formulation supports a steady, sustained blockade over 24 hours, counteracting the rapid systemic resistance drop that typically triggers the Baroreceptor Reflex. By causing a gradual rather than rapid reduction in resistance, this mechanism results in a dampened activation of the body's compensatory sympathetic nervous system.

Dosage and Administration Information

Oral Administration and Dosing Principles

Adalat LA is an oral, prolonged-release tablet containing nifedipine, intended for once-daily administration. The extended-release design mandates specific procedural rules: the tablet must be swallowed whole with water, and under no circumstances should it be crushed, chewed, or divided. This ensures the controlled, slow release of the active ingredient over a 24-hour period.

The dosing regimen is established according to individual needs. The typical starting dose is generally 30 mg or 60 mg once daily. Doses are subject to titration (gradual adjustment), often increased at intervals of 7 to 14 days, up to a maximum recommended dose of 120 mg once daily.

Administration Conditions and Restrictions

Instruction	Requirement
Frequency	Taken once daily, preferably at the same time each day.
Food Relationship	May be taken with or without food.
Special Restriction	Must not be taken with grapefruit juice, as this can affect the body’s processing of the drug.
Excretion Note	The tablet’s insoluble outer shell may be visible in the stool.

Population-Specific Use

Use in certain populations requires specific consideration. Patients with hepatic impairment require careful clinical monitoring and may necessitate a dose reduction due to altered drug clearance. While no specific dosage adjustment is typically required for patients with renal impairment, the use in older adults (over 65 years) may require a lower initial dose and careful observation. The treatment is designated for long-term maintenance.

Recent Clinical Evidence

Research Evidence for Persistent High Blood Pressure (Hypertension)

Research exploring this use has utilized Randomized Controlled Trials (RCTs) and Prospective Studies across large groups of adults, including older adults and those with heart risk factors. Researchers primarily monitored changes in systemic blood pressure and the frequency of major cardiovascular events. Findings describe patterns where observed outcomes related to event reduction were generally comparable across different established classes of blood pressure-lowering medications. Evidence for specific high-risk subgroups beyond those defined in the main trials remains limited.

Research Evidence for Chronic Stable Chest Pain (Angina Pectoris)

The evidence base for chronic stable chest pain is derived from RCTs and systematic reviews. Studies monitored symptom frequency and measured physical capacity through exercise tolerance testing. Evidence from regulatory reviews describes patterns that emphasize the need to distinguish findings from the prolonged-release (LA) formulation compared to older, immediate-release versions. A key limitation noted is the limited reliability of using short-term functional outcomes to predict major long-term health events.

Long-Term Studies and Durability of Research Data

The research includes long-term studies that monitored patients for extended periods, with follow-up durations lasting up to approximately five years. This research explored the durability of findings by tracking the consistency of physiological measurements and monitoring major events across these long time intervals.

Studies in Specific Patient Populations

Clinical research primarily focused on adults, including specific cohorts of older adults and groups defined by the presence of comorbidities. Regulatory documents note insufficient data or the complete absence of studies for use in children and adolescents. Results apply only to the populations studied.

Research Limitations and Areas of Uncertainty

The overall evidence landscape indicates that data for certain unique or rare subgroup findings are uncertain. For high blood pressure, results often show outcome equivalence between drug classes, meaning research highlights blood pressure control itself. Researchers also note the limitation regarding the ability of short-term functional tests to predict long-term health outcomes in angina patients.

Key Studies & References

Adalat LA 30 mg, prolonged-release tablets - Summary of Product Characteristics (SMPC)

Frequently Asked Questions (FAQ)

Common questions about Adalat LA (FAQ)

Q: How quickly should I expect to see an effect from Adalat LA?

The prolonged-release (LA) formulation is specifically designed to release the active ingredient slowly over 24 hours to ensure a sustained effect against high blood pressure or angina. Although the full therapeutic benefit builds over time, the active ingredient itself is absorbed relatively rapidly. Official documents state that the immediate-release form of the medication is detectable in the bloodstream within about 10 minutes.

Q: How long does a dose of Adalat LA typically last in the body?

Adalat LA is engineered to maintain a steady, consistent concentration of the active ingredient, nifedipine, over a full 24-hour period. While nifedipine is processed and eliminated by the body relatively quickly—with an elimination half-life of about two hours—the tablet's prolonged-release design ensures the consistent, long-acting effect.

Q: Do I need to avoid alcohol completely while taking Adalat LA?

Regulatory information indicates that alcohol may have additive effects with nifedipine in lowering blood pressure. This combination could increase the risk of side effects such as dizziness or lightheadedness. This may occur at the start of treatment, following a dose adjustment, or when restarting therapy after an interruption.

Q: Can older adults (seniors) use Adalat LA safely?

Adalat LA is used in older adults. However, regulatory documents describe the need for cautious dose selection, which often starts at the lower end of the dosing range. This approach reflects the generally higher frequency of reduced organ function that may occur in this population.

Q: What happens if I accidentally take a dose late?

Official product information contains specific directions on how to proceed if a single dose is missed. These instructions emphasize the need to avoid taking double doses to maintain the controlled release pattern. For specific guidance on administration, reference should be made to the full prescribing information.

Q: Can this medication affect my ability to drive or operate machinery?

Official safety information states that Adalat LA may cause side effects such as dizziness, faintness, extreme tiredness, or visual disturbances. Regulatory documents state that individuals who experience these effects may need to avoid driving or operating machinery. This is often noted to occur at the start of treatment, following a dosage increase, or with concurrent alcohol use.

Q: Is Adalat LA used for conditions other than high blood pressure?

Yes, in addition to high blood pressure, nifedipine is officially indicated for the management of certain types of chest pain. This includes the management of vasospastic angina and the management of chronic stable angina in patients who remain symptomatic despite other treatments or who cannot tolerate them.

Q: Can I take pain relievers like ibuprofen or acetaminophen with Adalat LA?

Regulatory interaction data indicates that certain pain relievers, such as ibuprofen (an NSAID), may potentially cause an increase in blood pressure when used with nifedipine. If used together, blood pressure monitoring may be necessary. Acetaminophen is not specifically noted in the key interactions sections of the official documents.

Q: Has Adalat LA been studied for use in Raynaud's phenomenon?

While the primary indications for this medicine are hypertension and angina, the active ingredient, nifedipine, is known to work by relaxing blood vessels. Some medical references describe studies for or the use of nifedipine off-label in the treatment of Raynaud's phenomenon.

Q: How long do people typically need to take Adalat LA for hypertension?

Treatment for chronic conditions like hypertension is designated for long-term maintenance. The medication may be continued indefinitely, subject to the ongoing clinical assessment and guidance of a healthcare professional.

Q: Is there a risk of withdrawal symptoms if I stop taking Adalat LA suddenly?

Official safety information describes that stopping Adalat LA suddenly without medical guidance is not recommended. Abrupt cessation of the medication may cause the underlying condition, such as angina or high blood pressure, to potentially worsen.

Q: Does Adalat LA affect blood sugar levels in non-diabetic people?

High blood sugar level is listed as a potential adverse reaction of unknown frequency in regulatory safety documents. Consultation with a healthcare provider is recommended if there are concerns about blood sugar levels or existing medications that may affect them.

Q: Is it generally considered a long-term or short-term treatment?

The treatment for chronic stable conditions like hypertension and angina with Adalat LA is designated for long-term maintenance. It is intended to be continued over an extended period.

Q: Are there any known issues with taking Adalat LA if I have kidney problems?

The processing of nifedipine in the body is not significantly influenced by the degree of renal impairment (kidney problems). Therefore, specific dose adjustments are typically not required for patients with kidney conditions, including those on dialysis.

Q: Is there a generic version of Adalat LA available?

Yes, the active ingredient is nifedipine extended-release tablets. This generic medicine is widely available and is approved by regulatory bodies as a pharmaceutical equivalent to the brand-name product.

Q: Is Adalat LA known to affect sexual function?

Official safety information lists loss in sexual ability, desire, drive, or performance as a possible adverse effect of unknown frequency. Separately, high-dose studies in rats have shown evidence of reduced fertility.

Q: Are there specific interactions with common vitamins or supplements?

While the label details interactions with certain strong enzyme inhibitors and inducers, interaction data also indicates that some multivitamins with minerals may potentially decrease the effect of nifedipine. If used together, blood pressure monitoring may be clinically relevant.

Q: Does Adalat LA cause weight gain?

Regulatory documents list unusual weight gain or loss as a potential side effect. Weight change may also be associated with peripheral oedema (swelling or fluid retention) which is a common effect of the medication.

Q: Is Adalat LA appropriate for someone who has previously had a heart attack?

Official warnings state that Adalat LA is contraindicated and should not be used if a patient has had a heart attack within the past two weeks.

Q: How does the Extended Release (LA) formulation work to maintain a consistent effect?

The tablet is engineered with a special polymer matrix or a controlled delivery system that carefully manages the rate at which nifedipine is released. This specialized mechanism ensures a steady, sustained concentration of the drug is maintained in the body over the entire 24-hour period for consistent therapeutic effect.

Q: What research is available on Adalat LA and stroke risk reduction?

Research on high blood pressure treatments, including nifedipine, often monitors major cardiovascular events, which can include stroke. Regulatory documents note that studies have examined the risk of stroke, particularly in relation to the use of short-acting forms of nifedipine in older adults.

How should Adalat LA be stored and disposed of?

How to Store and Dispose of Adalat LA

The storage and disposal of Adalat LA (nifedipine prolonged-release tablets) must follow official requirements to ensure stability and public safety.

Storage Requirements

The tablets must be stored at a temperature not exceeding 30 C and should be kept from freezing. The product is highly sensitive and requires protection from strong light and moisture. To maintain these conditions, the tablets must remain in the original container/blister strip until the time of use.

Constraint	Requirement
Temperature	Store below 30 C (do not freeze)
Protection	Keep protected from strong light and moisture
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Adalat LA must not be disposed of in household rubbish or flushed down the toilet. The medication must be returned to a pharmacist (chemist) or a designated pharmaceutical take-back location for proper and environmentally safe disposal.

Adalat LA